Literature DB >> 20237039

18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial.

Arun Abraham1, Graham Nichol, Kathryn A Williams, Ann Guo, Robert A deKemp, Linda Garrard, Ross A Davies, Lloyd Duchesne, Haissam Haddad, Benjamin Chow, Jean DaSilva, Rob S B Beanlands.   

Abstract

UNLABELLED: (18)F-FDG PET may assist decision making in ischemic cardiomyopathy. The PET and Recovery Following Revascularization (PARR 2) trial demonstrated a trend toward beneficial outcomes with PET-assisted management. The substudy of PARR 2 that we call Ottawa-FIVE, described here, was a post hoc analysis to determine the benefit of PET in a center with experience, ready access to (18)F-FDG, and integration with clinical teams.
METHODS: Included were patients with left ventricular dysfunction and suspected coronary artery disease being considered for revascularization. The patients had been randomized in PARR 2 to PET-assisted management (group 1) or standard care (group 2) and had been enrolled in Ottawa after August 1, 2002 (the date that on-site (18)F-FDG was initiated) (n = 111). The primary outcome was the composite endpoint of cardiac death, myocardial infarction, or cardiac rehospitalization within 1 y. Data were compared with the rest of PARR 2 (PET-assisted management [group 3] or standard care [group 4]).
RESULTS: In the Ottawa-FIVE subgroup of PARR 2, the cumulative proportion of patients experiencing the composite event was 19% (group 1), versus 41% (group 2). Multivariable Cox proportional hazards regression showed a benefit for the PET-assisted strategy (hazard ratio, 0.34; 95% confidence interval, 0.16-0.72; P = 0.005). Compared with other patients in PARR 2, Ottawa-FIVE patients had a lower ejection fraction (25% +/- 7% vs. 27% +/- 8%, P = 0.04), were more often female (24% vs. 13%, P = 0.006), tended to be older (64 +/- 10 y vs. 62 +/- 10 y, P = 0.07), and had less previous coronary artery bypass grafting (13% vs. 21%, P = 0.07). For patients in the rest of PARR 2, there was no significant difference in events between groups 3 and 4. The observed effect of (18)F-FDG PET-assisted management in the 4 groups in the context of adjusted survival curves demonstrated a significant interaction (P = 0.016). Comparisons of the 2 arms in Ottawa-FIVE to the 2 arms in the rest of PARR 2 demonstrated a trend toward significance (standard care, P = 0.145; PET-assisted management, P = 0.057).
CONCLUSION: In this post hoc group analysis, a significant reduction in cardiac events was observed in patients with (18)F-FDG PET-assisted management, compared with patients who received standard care. The results suggest that outcome may be benefited using (18)F-FDG PET in an experienced center with ready access to (18)F-FDG and integration with imaging, heart failure, and revascularization teams.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237039     DOI: 10.2967/jnumed.109.065938

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

Review 1.  Imaging myocardial metabolic remodeling.

Authors:  Robert J Gropler; Rob S B Beanlands; Vasken Dilsizian; E Douglas Lewandowski; Flordeliza S Villanueva; Maria Cecilia Ziadi
Journal:  J Nucl Med       Date:  2010-05-01       Impact factor: 10.057

2.  Patient-centered imaging.

Authors:  E Gordon Depuey; John J Mahmarian; Todd D Miller; Andrew J Einstein; Christopher L Hansen; Thomas A Holly; Edward J Miller; Donna M Polk; L Samuel Wann
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

Review 3.  Prognosis in the era of comparative effectiveness research: where is nuclear cardiology now and where should it be?

Authors:  Leslee J Shaw; Fadi G Hage; Daniel S Berman; Rory Hachamovitch; Ami Iskandrian
Journal:  J Nucl Cardiol       Date:  2012-10       Impact factor: 5.952

4.  Diagnosis and prognosis of coronary artery disease: PET is superior to SPECT: Pro.

Authors:  Rob S B Beanlands; George Youssef
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

5.  The case for cardiac magnetic resonance and positron emission tomography multimodality imaging of myocardial viability.

Authors:  George A Beller
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

Review 6.  Effects of radiation exposure from cardiac imaging: how good are the data?

Authors:  Andrew J Einstein
Journal:  J Am Coll Cardiol       Date:  2012-02-07       Impact factor: 24.094

7.  Sample size considerations for clinical research studies in nuclear cardiology.

Authors:  Cody Chiuzan; Erin A West; Jimmy Duong; Ken Y K Cheung; Andrew J Einstein
Journal:  J Nucl Cardiol       Date:  2015-09-24       Impact factor: 5.952

8.  Ischaemic vs non-ischaemic dilated cardiomyopathy: The value of nuclear cardiology techniques.

Authors:  Federico Caobelli; Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2015-07-08       Impact factor: 5.952

Review 9.  PET/MRI: current state of the art and future potential for cardiovascular applications.

Authors:  Nebiyu Adenaw; Michael Salerno
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

10.  Ischemic Mitral Regurgitation: Abnormal Strain Overestimates Nonviable Myocardium.

Authors:  Ashley E Morgan; Yue Zhang; Mehrzad Tartibi; Samantha Goldburg; Jiwon J Kim; Thanh D Nguyen; Julius Guccione; Liang Ge; Jonathan W Weinsaft; Mark B Ratcliffe
Journal:  Ann Thorac Surg       Date:  2018-01-31       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.